Clinical trials
Phase 3 Lung Neoplasms trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2001 | 2 |
| 2002 | 2 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 3 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 43 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Istituto Nazionale per lo Studio e la Cura dei Tumori | 3 |
| AstraZeneca | 2 |
| Tang-Du Hospital | 2 |
| The Christie NHS Foundation Trust | 2 |
| Cambridge University Hospitals NHS Foundation Trust | 1 |
| Cancer Research UK | 1 |
| Commissie Voor Klinisch Toegepast Onderzoek | 1 |
| Consorzio Oncotech | 1 |
| EBMT Solid Tumors Working Party | 1 |
| European Institute of Oncology | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 43 |
| Carcinoma, Non-Small-Cell Lung | 19 |
| Lung Diseases | 3 |
| Neoplasms | 3 |
| Bronchial Neoplasms | 2 |
| Carcinoma, Bronchogenic | 2 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Respiratory Tract Diseases | 2 |
| Thoracic Neoplasms | 2 |
| Adenocarcinoma of Lung | 1 |
Trials
Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.